Aim To evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosis of amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in (iii) ALS and (iv) HD patients. Methods Four comprehensive literature searches were conducted using the PICO model to extract evidence from relevant studies. An expert panel then voted using the Delphi method on these four diagnostic scenarios. Results The availability of evidence was good for FDG-PET utility to support the diagnosis of ALS, poor for identifying presymptomatic subjects carrying HD mutation who will convert to HD, and lacking for identifying cognitive-related metabolic changes in both ALS and HD. After the Delphi consensual procedure, the panel did not support the clinical use of FDG-PET for any of the four scenarios. Conclusion Relative to other neurodegenerative diseases, the clinical use of FDG-PET in ALS and HD is still in its infancy. Once validated by disease-control studies, FDG-PET might represent a potentially useful biomarker for ALS diagnosis. FDG-PET is presently not justified as a routine investigation to predict conversion to HD, nor to detect evidence of brain dysfunction justifying cognitive decline in ALS and HD.
Background
The lack of clinical guidelines for the use of FDG-PET in the diagnosis of dementia and other neurodegenerative diseases has led the European Association of Nuclear Medicine (EANM) and the European Academy of Neurology (EAN) to launch a joint initiative to guide clinicians in the use of the exam. The initiative included a set of 21 clinical questions, to be addressed based on literature evidence and expert consensus [1] .
In this paper, we report the evidence assessment performed to evaluate the incremental value of FDG-PET over clinical tests in: (i) diagnosing amyotrophic lateral sclerosis (ALS); (ii) picking early signs of neurodegeneration in patients with a genetic risk of Huntington's disease (HD); and detecting metabolic changes related to cognitive impairment in patients with (iii) ALS and (iv) HD. Four literature searches were performed to assess the quality of evidence supporting the accuracy of FDG-PET in the previously mentioned conditions.
Methods
Seven panelists, four from EANM and three from EAN, were appointed to produce recommendations taking into account the incremental value of FDG-PET, as added on clinical examination, for the evaluation of ALS and HD. Consensus recommendations were provided through a Delphi procedure, where panelists were encouraged to vote based on the available evidence and their expertise [2] .
The methods for the project are described in detail elsewhere in this issue [2] . Briefly, we performed literature searches using harmonized PICO (Population, Intervention, Comparison, Outcome) question keywords edited by the experts, screened the studies for eligibility, extracted the data to assess their methodology quality, and provided an evidence assessment consistent with the EFNS guidance [3] , and specific to the aim of assessing FDG-PET accuracy studies [2] .
PICO question(s) for this paper
For this review, the PICO questions were whether FDG-PET should be performed, as adding diagnostic value (in terms of increased accuracy, and versus clinical confirmation) as compared to standard clinical assessment alone, to: 
Eligibility criteria
Only original full papers published in English on international impacted journals were considered, excluding reviews, management guidelines, abstracts and gray literature. Minimum sample sizes were set a priori at 10 for PICOs 17 and 19, 5 for PICO 18, and 20 for PICO 20.
Literature search
Electronic search strategy, developed and tested with panelists, was performed through predefined keywords strings, grounding on the specific PICO question and including a selection of terms taken from a largely inclusive literature selection, in order to pick all variants for the same keyword. The strings were made up of a common part for FDG-PET and of a PICO-specific part [2] . Literature searches were performed using the Medline and Embase databases, and included papers published online until November 2015. First, an independent screening of all included papers was performed by a neurologist or by a nuclear medicine physician with expertise in neurodegenerative disorders, who could include additional papers based on personal knowledge or tracking from references of papers. Then, the full texts of these potentially eligible studies were independently assessed for eligibility by the methodology group [2] .
Data extraction and quality assessment
We extracted data to evaluate study features, population of interest, index test, gold/reference standard, critical/proxy outcomes, FDG-PET image assessment (visual or semiquantitative methods), risk of bias, index test imprecision, applicability, effect size, and effect inconsistency [2] . Data extractor for this review was DA. Critical outcomes were validated measures of test performance (accuracy, sensitivity, specificity, AUC, positive and negative predictive values and likelihood ratios). An additional proxy outcome was admitted for PICO 19, consisting of a significant FDG-PET hypometabolic pattern associated to presymptomatic HD gene carriers who subsequently develop HD, using clinical conversion at follow-up as the reference standard.
Evidence was assessed relative to individual studies ( h t t p s : / / d r i v e . g o o g l e . c o m / o p e n ? i d = 0 B 0 _ JB3wzTvbpVFYtUGxHdGZWYmc) and by outcome. A final assessment was formulated, summarizing the relative availability of evidence, i.e. ranking the quality and availability of evidence of this PICO among all of the 21 PICOs of the project. This ranking was summarized as very poor/lacking, poor, fair or good.
Results
For the four PICOs included in this review, 290 papers were identified by the referent panelist (FA). Fifty-three studies reported the comparison of interest and were examined by the methodology group. Of these, only four contained the critical outcomes, properly quantifying FDG-PET diagnostic utility (Fig. 1) . The evidence assessment denoted a good evidence of FDG-PET utility to support the diagnosis of ALS and a poor evidence in picking neurodegeneration in presymptomatic subjects carrying HD mutation. Semi-quantitative evidence was lacking for assessing FDG-PET utility to identify ALS-related brain dysfunction justifying cognitive impairment in ALS patients, and frontal-lobe hypometabolism responsible for cognitive decline in patients with HD. After the Delphi consensual procedure, the panel did not support the clinical use of FDG-PET for any of the four aims ( Table 1 , [1] ).
PICO 17: Use of FDG-PET to confirm clinical diagnosis of ALS
Among the 74 papers identified and screened, 16 were sent to the methodology group for data extraction and assessment (see Fig. 1 -PICO 17) . Eight papers were excluded for the following reasons: four papers [5] [6] [7] [8] did not have the minimum sample size; two studies used a different index test (Oxygen-15 PET) [9, 10] ; Chiò et al., (2010) [11] is a case report study; and Carluer et al., (2015) [12] aimed to investigate the neural substrate of theory of mind deficits in ALS patients. Among the remaining eight papers, critical outcomes on FDG-PET diagnostic utility in ALS were available in two [13, 14] (see Table 2 -PICO 17; data extraction table available at https://drive.google.com/file/d/0B0_ JB3wzTvbpWDhwaF8zSGdCd3c/view?usp=sharing). The two papers [13, 14] , including a total of 265 ALS patients and 60 healthy controls, showed that the metabolism of specific regions of interest distinguished ALS patients from healthy controls with high sensitivity (95.4 and 94.8%, respectively), specificity (82.5 and 80%, respectively), and accuracy (93.2 and 91.8%, respectively). The remaining six studies provided only evidence of hypometabolism in ALS patients relative to controls without diagnostic outcomes [15] [16] [17] [18] [19] [20] . The most common metabolic pattern in ALS patients compared to healthy controls consisted of hypometabolism in the frontal (primarily in motor, premotor and prefrontal cortex) and occipital lobes (Figure 2a ). Relative hypermetabolism was consistently observed in the brainstem (midbrain and pons), medial temporal lobe (including hippocampus), cerebellum and amygdalae.
The relative availability of evidence, as ranked among the 21 PICOs of the whole project, supporting diagnostic utility of FDG-PET in distinguishing patients with ALS from healthy people was ranked as good. However, the consensual recommendation for PICO 17 was defined on Delphi round II, with six panelists not supporting clinical utility of FDG PET in the diagnosis of ALS, based on the greater utility of other instruments and the limited number of studies. PICO 18: Use of FDG-PET to detect cognitive-related brain dysfunction in ALS Thirty-one papers were identified and screened, but only five were qualified for further analysis and sent to the methodology team for evidence assessment (see Fig. 1 -PICO 2). Of these, one paper was excluded because not pertinent [21] . The data extraction table is available at https://drive.google.com/file/d/ 0B0_JB3wzTvbpUXBqWGZfd0VQVkk/view?usp=sharing.
Diagnostic outcomes were not available in any of the examined papers, denoting lack of objective evidence in supporting the incremental diagnostic value of FDG-PET in identifying ALS patients with cognitive impairment as compared to clinical/neuropsychological assessment. Papers were assessed anyway considering the available results, in order to provide potentially useful information to panelists' decisions. All the four studies reported findings on the relation between hypometabolic patterns and cognitive dysfunction in ALS. Hypometabolism was frequently observed in the frontal cortex, consistent with a clinical picture of FTD [12, 22, 23] , especially in its behavioral variant [22] (Figure 2a) . Hypometabolism in such patients was related to impairment in word fluency [19, 22] , psychomotor speed, and sustained attention [22] . Finally, a study showed a correlation between frontal hypometabolism and theory of mind deficits in ALS patients [12] .
Since these findings are based on correlation data rather than on evidence of test performance, the availability of formal evidence of FDG-PET clinical utility in detecting cognition-related brain dysfunction in ALS patients was considered to be lacking. No agreement was reached through the Delphi procedure for this PICO. The panel concluded that FDG-PET may have diagnostic and prognostic value in selected cases, but no recommendation can be formulated based on either data nor on the consensus procedure.
PICO 19: FDG-PET to predict HD in presymptomatic subjects carrying HD gene mutation Among the 144 papers identified, 26 were eligible for further assessment and sent to the methodology team (see Fig. 1 -PICO 19) . Eighteen papers were excluded for the following reasons: in two studiesPETscans were obtained using radiotracers other than FDG [24, 25] ; two studies did not reach the recommended minimum sample size [26, 27] ; seven papers did not include the target population (i.e.,subjectswere not Batgenetic risk forHD^,buttheywere already HD patients) [28] [29] [30] [31] [32] [33] [34] ; in six papers, subjects were considered at risk based on positive family history, but a genetic test was not performed [35] [36] [37] [38] [39] [40] ; and in one study, FDG-PET results were not reported although the scans were obtained [41] . Eight papers included the comparison of interest. The data extraction table is available at https://drive.google.com/file/d/0B0_ JB3wzTvbpRkVja29fMTdRVTg/view?usp=sharing.
Critical outcomes were available in only one paper (see Table 3 -PICO 19) [42] , which showed that striatal FDG-PET uptake was able to identify presymptomatic HD subjects who will convert to manifest HD with an area under the ROC curve of 0.94 for caudate and 0.80 for putamen. Clinical conversion at follow-up was used as the reference standard [42] . Hypometabolism in the striatum (i.e., caudate and putamen) in presymptomatic mutation carriers who subsequently develop HD as compared to non-converters was found in three additional studies [43] [44] [45] , but diagnostic values were not reported.
Other studies provided only evidence of striatal hypometabolism associated to presymptomatic HD gene carriers as compared to healthy controls [46] [47] [48] [49] . Although such metabolic patterns cannot be uniquely attributed to HDrelated neurodegeneration since no information about the subjects' conversion into HD was provided, it is interesting to note that it is consistent with the patterns observed relative to non-converters [42] (Fig. 2b) .
Relative to the evidence available for the other PICOs, the availability of formal evidence supporting clinical utility of FDG-PET in identifying subjects with a genetic risk of HD was ranked as poor. The consensual recommendation for PICO 19 was defined on Delphi round II, with six panelists recommending not to support FDG-PET use in clinical settings and limiting it to research purposes.
PICO 20: FDG-PET to detect frontal-lobe hypometabolism responsible for cognitive deterioration in patients with HD Among the 41 papers identified and screened, six were provided to the methodology team for data extraction and assessment (see Fig. 1 -PICO 7) . Two papers were excluded as one Outcome quality: summary of evidence as from all columns study included presymptomatic HD mutation carriers [44] , while in the second one patients did not undergo neuropsychological assessment, with consequent lack of an objective confirmation of Bcognitive deterioration^ [32] . Critical outcomes on FDG-PET diagnostic utility in picking frontal-lobe hypometabolism in HD patients were available in only one of the four examined papers [50] (see Table 4 -PICO 20; data extraction table available at https://drive.google.com/ file/d/0B0_JB3wzTvbpWlF4a2RQMU9WWVU/view?usp= sharing).
This study showed hypometabolism in eight HD patients compared to healthy controls, in prefrontal and premotor regions [50] . Moreover, a significant correlation was found between frontal lobe hypometabolism and cognitive performance, as measured by means of a series of script generation and script sorting tasks [50] (see last line in Table 4 - PICO 20) .
The remaining three papers did not provide critical outcomes. One study did not assess frontal cortical metabolism, since the analyses was limited to caudate, putamen and thalamus [51] . Kuwert et al., 1990 [30] found that cerebellar metabolism correlated with the degree of dementia (which was determined using a score derived from a psychometric test battery), but correlations between frontal metabolism and neuropsychological tests were not reported. In a third study [38] , frontal, temporal and parietal metabolism was lower in HD cases with dementia as compared with those without dementia and controls, but correlation with cognitive performance was not examined in greater detail.
The availability of evidence was considered to be lacking. Agreement was achieved on Delphi round III, with five panelists not supporting clinical use of FDG-PET in detecting frontal-lobe hypometabolism responsible for cognitive decline in patients with HD.
Discussion
In this paper, we assessed the evidence in supporting the clinical utility of FDG-PET in ALS and HD patients, in the context of 21 scenarios related to the use of FDG-PET in the diagnosis of neurodegenerative disorders [1] .
ALS diagnosis is based on clinical history, neurologic examination and symptom progression and is supported by neurophysiological testing. Several FDG-PET studies in small samples of FTD patients with motor neuron disease and further investigations in larger ALS cohorts have shown significant differences of metabolism relative to healthy controls [5] [6] [7] [8] [15] [16] [17] [18] [19] [20] . Hypometabolism in the primary motor and premotor cortices, but also in the frontal and parietal lobes was observed. Relative hypermetabolism was also found in the mediotemporal cortex, cerebellum, and brainstem. Up to November 2015, two studies [13, 14] evaluated the value of FDG-PET in large prospective cohorts of patients with ALS around the time of diagnosis. Overall, the diagnostic value of FDG-PET versus a control population showed high accuracy. However, the specific search of metabolic abnormalities for the purpose of making a firm diagnosis of ALS was not recommended by the panelists. The uniformly proposed reasons (during the Delphi panel procedure) for not supporting the use of FDG-PET in the clinical diagnosis of ALS mainly relied on the availability of other routine exams that are more directly informative for this disease (i.e., clinical signs of motor impairment and neurophysiological testing). Importantly, the panelists also recognized that the implementation of FDG-PET in the standard diagnostic work-up would need validation of its specificity to discriminate ALS patients from subjects with disease mimics. Finally, the clinical value of FDG-PET in ALS patients would be enhanced by studies investigating its sensitivity in detecting upper motor neuron involvement before clinical symptoms become apparent (i.e., in patients with the lower motor neuron variant of the disease). Of note, two large FDG-PET studies in ALS [52, 53] have been published after November 2015 including 259 and 175 patients, respectively. Although they were not included in the evidence originally assessed and used to achieve the consensus recommendations, it is worth noting that the overall accuracy in discriminating ALS patients from healthy controls was above 99% [52, 53] . While recognizing the additional evidence provided by these recent studies [52, 53] , we also believe that the panel's conclusions would not have changed as the accuracy of FDG-PET was not tested against clinical and neurophysiological tests nor in separating ALS patients from ALS-mimicking disorders.
Cognitive impairment and behavioral symptoms affect approximately 50% of people with ALS, of whom 15% develop FTD [54] . Research has indicated that cognitive and behavioral deficits are associated with reduced survival, disengagement with life prolonging interventions, and increased caregiver burden [55] . Thus, clinical utility in detecting brain dysfunction related to cognitive and behavioral deterioration in patients with ALS has long been recognized. Advances in MRI have enabled mapping of functional and structural abnormalities extending beyond the motor system [55] . Evidence is increasing that FDG-PET shows hypometabolism in ALS patients with cognitive and/or behavioral abnormalities [12, 19, 22, 23] . Panelists recognized that functional neuroimaging with FDG-PET, additionally or alternatively to structural MRI, is required by the current diagnostic criteria for probable FTD at the dementia stage [56] . On the other hand, the clinical utility of FDG-PET in ALS patients with cognitive and/or behavioral changes not fulfilling clinical criteria for FTD diagnosis is more controversial. There is no objective evidence so far for an incremental diagnostic value of FDG-PET versus comprehensive cognitive and behavioral testing to allow attributing such deficits to ALS pathology. In agreement with the Strong consensus criteria [54] , the panelists suggested that FDG-PET is adequate for research purposes or in selected cases to verify the expected pattern of abnormality while it is not yet recommended to be of general utility clinically. Larger longitudinal studies involving patients at disease onset are needed to evaluate whether FDG-PET can have a useful role in understanding the mechanisms underlying ALS-related cognitive or behavioral deficits along the disease course. Sequencing errors (a displacement in the logical sequence of actions within a script) were used to evaluate the temporal aspect of the script. Boundary errors (when the generation of events stops short of the stated endpoint or extends beyond this point) were used to evaluate the temporal dimension of the script. Perseverative errors consist of actions that are repeated more than once in a script
Relative to the other PICOs, our assessment denoted poor availability of evidence that FDG-PET is clinically useful in picking neurodegeneration in patients at genetic risk of HD. Striatal hypometabolism may be an earlier finding as compared to striatal volume loss on MRI [42] [43] [44] [45] . Additionally, one study showed that decreases in putaminal and caudate metabolism identified presymptomatic subjects carrying HD gene mutation who developed manifest motor symptoms suggestive of HD after as many as 5 years from PET scan [42] . However, the paucity of studies in this field together with the present lack of effective neuroprotective drugs led the panelists to suggest that FDG-PET is not justified as a routine investigation to predict conversion to overt HD. As in the case of ALS, additional evidence on the value of FDG-PET in predicting conversion of presymptomatic HD into manifest HD was investigated by a study published after November 2015 [57] . Lopez-Mora et al. found a significant striatal hypometabolism in 18 HD patients relative to 15 presymptomatic gene-expanded carriers but the actual discriminative value was not reported [57] . Although striatal hypometabolism was also observed in the group of premanisfest HD subjects compared with healthy controls, regardless of the time to disease onset, individual standard uptake values overlapped between groups [57] . Finally, only one study explored the correlations between patterns of hypometabolism and cognitive performance in a very small sample of HD patients [50] . Based on the current knowledge, panelists agreed that FDG-PET would not add clinically useful information to detect frontal-lobe hypometabolism responsible for cognitive deterioration in known HD patients. The reason for the negative response by the majority of the panelists was based on the lack of data.
Relative to other neurodegenerative diseases [1] , the use of FDG-PET in ALS and HD is still in its infancy. Therefore, an important limitation of this work was the paucity, or, in some circumstances, complete lack of evidence on which to base panelists' recommendations. Collection of more robust formal evidence is required to demonstrate the clinical value of FDG-PET in these two conditions. In addition, combining application of tracers, targeting different pathological processes like neuroinflammation and excitotoxicity, might provide novel insights to facilitate diagnosis in complex neurodegenerative diseases like ALS and HD. Finally, more widespread implementation of simultaneous hybrid PET-MRI scanners might aid in developing multiparametric markers for further characterization of the diseases.
